AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 151 min read$AZZ

B. Riley Securities maintains Buy rating on AZZ, $174 price target

B. Riley Securities kept a Buy rating and $174 price target on AZZ, implying 26.4% upside. AZZ reported record fiscal 2Q27 adjusted EBITDA of $110.9M, exceeding estimates, and raised FY27 guidance, citing growth opportunities and new projects.

Original reporting
tradingview.com
Published Oct 15, 2026, 1:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 1:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
B. Riley Securities maintains Buy rating on AZZ, $174 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$AZZBullishLow
01

Why it matters

The upgrade could prompt short-term buying, but lacks a strong catalyst for a large move.

02

Market read

Provides a modestly bullish signal for AZZ, with limited broader market impact.

03

What to watch

No mention of competitive pressures or pipeline risks that could temper upside.

Relevance 6/10Novelty 5/10Timing: today

Background

Analyst note from B. Riley on AZZ's Q2 performance and FY27 outlook.

Company-level read

Ticker impact

$AZZBullishMedium confidence
Context

B. Riley upgraded AZZ with a $174 price target, citing record Q2 adjusted EBITDA and raised FY27 guidance.

Expected impact

potential upward pressure as investors price in the new target

Evidence & confidence

The rating and target are new but lack a concrete catalyst beyond earnings, so impact is modest.

Market effects

Sector

May lift sentiment in the healthcare/biotech sector as peers see a higher target.

Regional

Limited to US-listed healthcare stocks.

Global

Low, confined to AZZ investors.

Counterpoint

What could challenge this read

The price target may be overly optimistic given broader market volatility.

Key entities

  • Analyst
    B. Riley Securities

    Maintains Buy rating and raises price target to $174.

  • Company
    AZZ

    Reported record Q2 adjusted EBITDA and raised FY27 guidance.

Read at source← All news

Related articles

OCT 26
$AZZMed

INVESTMENTTHESIS Why Own AZZ Five structural reasons why AZZ can compound shareholder returns and outperform the market over a multi-year horizon. Unrivaled…

AZZ INC (AZZ) filed an SEC Form 8-K — Regulation FD Disclosure. N Y S E : A Z Z | I N V E S T O R P R E S E N T A T I O N North America's Leading Independent Metal Coatings Platform A differentiated, high-margin hot-dip galvanizing and coil coating company, compounding earnings through secular tailwinds, disciplined capital allocation, and a

SEC EDGAR 8-K2 min
OCT 14
$AZZHighAI 8/10

AZZ Inc (AZZ) (Q2 2027) Earnings Call Highlights: Record Sales, Raised Guidance, and a 29% EPS Jump

AZZ Inc reported Q2 2027 earnings with record sales, raised guidance, and a 29% EPS jump. The company cited strong demand in Metal Coatings and the Seattle Galvanizing acquisition's performance. Challenges include softer HVAC volume, tight steel substrate markets, and potential margin pressure from tariffs. The debt reduction target was lowered to $100-$140 million due to the acquisition.

finance.yahoo.com2 min
OCT 14
$AZZMedAI 8/10

What AZZ (AZZ) Said on Its Q2 Earnings Call

AZZ Inc. reported Q2 earnings, highlighting the acquisition of Seattle Galvanizing and organic expansions. Sales grew in construction, industrial, and transportation sectors. The company raised its fiscal 2027 outlook, expecting sales of $1.825B-$1.875B and adjusted EBITDA of $380M-$420M. AZZ also updated its debt reduction target due to the acquisition.

finance.yahoo.com2 min
OCT 14
$AZZHighAI 8/10

AZZ (AZZ) Q2 2027 Earnings Call Transcript

AZZ reported Q2 2027 earnings with record sales of $486.9M, up 16.7% YoY. Metal Coatings sales rose 22.9%, while Precoat Metals sales increased 11.5%. Adjusted EPS grew 29% to $2.00. The company completed the Seattle Galvanizing acquisition and is expanding capacity in key markets. Operating cash flow was $102.8M, with adjusted EBITDA at $110.9M. The Washington, Missouri facility is ramping up as planned, contributing to profitability.

finance.yahoo.com3 min
OCT 14
$AZZMed

Barclays initiates AZZ stock with Equalweight rating on valuation

Barclays initiated coverage on AZZ Inc. (NYSE:AZZ) with an Equalweight rating and $140 price target, citing its market position and growth prospects. The stock trades at $136.71, below both the target and InvestingPro’s Fair Value of $139.07. Barclays noted AZZ’s pricing power, market share gains, and accretive greenfield plant, but believes positives are reflected in the share price.

investing.com1 min